Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Akshay Sharma, Neel S. Bhatt, Andrew St. Martin, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 3, pp. e185-e193
Open Access | Times Cited: 339

Showing 26-50 of 339 citing articles:

Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis
Moazzam Shahzad, Sibgha Gull Chaudhary, Muhammad Usman Zafar, et al.
Transplant Infectious Disease (2022) Vol. 24, Iss. 2
Closed Access | Times Cited: 41
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Alessandro Busca, Jon Salmanton‐García, Francesco Marchesi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
Matthew G. Johnson, Julie Strizki, Michelle Brown, et al.
Infection (2023) Vol. 51, Iss. 5, pp. 1273-1284
Open Access | Times Cited: 29
Alterations in Gut Microbiota Composition in Patients with COVID-19: A Pilot Study of Whole Hypervariable 16S rRNA Gene Sequencing
Dorota Mańkowska‐Wierzbicka, Joanna Żuraszek, Adrianna Wierzbicka, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 367-367
Open Access | Times Cited: 29
Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre–Cellular Therapy SARS-CoV-2 Infection
Ila Nimgaonkar, Leah H Yoke, Pavitra Roychoudhury, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 1, pp. 86-95
Closed Access | Times Cited: 10
How Immunocompromised Hosts Were Left Behind in the Quest to Control the Covid-19 Pandemic
Michael Boeckh, Steven A. Pergam, Ajit P. Limaye, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 9
Exploring the Dynamics of SARS-CoV-2 and HIV Co-infection: Mutation Risks, Therapeutic Efficacy, and Future Variant Prevention
Sumaiya Tasnim Maliha, Rabeya Fatemi, Marjana Akter, et al.
Diagnostic Microbiology and Infectious Disease (2025) Vol. 111, Iss. 3, pp. 116707-116707
Closed Access | Times Cited: 1
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients
Muhammad Umair Mushtaq, Moazzam Shahzad, Sibgha Gull Chaudhary, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 9, pp. 796.e1-796.e7
Open Access | Times Cited: 54
NKG2D Natural Killer Cell Receptor—A Short Description and Potential Clinical Applications
Jagoda Siemaszko, Aleksandra Marzec-Przyszlak, Katarzyna Bogunia‐Kubik
Cells (2021) Vol. 10, Iss. 6, pp. 1420-1420
Open Access | Times Cited: 52
Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019
Ghady Haidar, John W. Mellors
Clinical Infectious Diseases (2021) Vol. 73, Iss. 6, pp. e1397-e1401
Open Access | Times Cited: 51
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Lorenzo Canti, Stéphanie Humblet‐Baron, Isabelle Desombere, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 51
COVID-19 and Cancer
Aakash Desai, Turab Mohammed, Narjust Duma, et al.
JAMA Oncology (2021) Vol. 7, Iss. 12, pp. 1882-1882
Open Access | Times Cited: 50
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement
Saúl Reyes, Anthony L. Cunningham, Tomáš Kalinčík, et al.
Journal of Neuroimmunology (2021) Vol. 357, pp. 577627-577627
Open Access | Times Cited: 48
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients
Muneyoshi Kimura, Victor H. Ferreira, Sagar Kothari, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 10, pp. 706.e1-706.e10
Open Access | Times Cited: 35
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 33
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101983-101983
Open Access | Times Cited: 21
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Per Ljungman, Gloria Tridello, José Luís Piñana, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells
Thi H. O. Nguyen, Louise C. Rowntree, Lilith F. Allen, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 4, pp. 101017-101017
Open Access | Times Cited: 17
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 542-554
Closed Access | Times Cited: 8
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses
Juliet Meir, Muhammad Abbas Abid, Muhammad Bilal Abid
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 12, pp. 973-987
Open Access | Times Cited: 39
Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Anne‐Claire Mamez, Amandine Pradier, Federica Giannotti, et al.
Bone Marrow Transplantation (2021) Vol. 56, Iss. 12, pp. 3094-3096
Open Access | Times Cited: 37
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Arielle Elkrief, Julie Wu, Chinmay Jani, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 303-330
Open Access | Times Cited: 35
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review
Valentina Bonuomo, Isacco Ferrarini, Michele Dell’Eva, et al.
World Journal of Virology (2021) Vol. 10, Iss. 6, pp. 312-325
Open Access | Times Cited: 34
Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients
Sandra Easdale, Robyn Shea, Lauren Ellis, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 10, pp. 880.e1-880.e4
Open Access | Times Cited: 33

Scroll to top